Theravance Biopharma (TBPH) Current Assets (2013 - 2026)

Theravance Biopharma (TBPH) has reported Current Assets for 14 consecutive years, with $417.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Assets rose 177.93% year-over-year to $417.6 million; the TTM figure through Mar 2026 stood at $417.6 million (up 177.93% YoY), while the FY2025 annual figure was $418.5 million, up 159.8% from the prior year.
• Current Assets steadied at $417.6 million in Q1 2026 per TBPH's latest filing, from $418.5 million in the prior quarter.
• Across five years, Current Assets topped out at $511.7 million in Q3 2022 and bottomed at $116.5 million in Q3 2024.
• Historically, Current Assets has averaged $247.2 million across 5 years, with a median of $192.0 million in 2023.
• Annual changes were most pronounced in 2023 — Current Assets slumped 68.4% — and 2025, when it jumped 207.02%.
• Theravance Biopharma's Current Assets stood at $353.5 million in 2022, then plunged by 62.22% to $133.5 million in 2023, then grew by 20.61% to $161.1 million in 2024, then jumped by 159.8% to $418.5 million in 2025, then slipped by 0.2% to $417.6 million in 2026.
• Business Quant data shows TBPH's Current Assets at $417.6 million in Q1 2026, $418.5 million in Q4 2025, and $354.7 million in Q3 2025.